Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kazuhiko Nakagawa

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer

Cancer Research

Oncology

2020

English

NDRG1/Cap43/Drg-1 May Predict Tumor Angiogenesis and Poor Outcome in Patients With Lung Cancer

Journal of Thoracic Oncology

English

Aberrant HER3 Ligand Heregulin-Expressing Head and Neck Squamous Cell Carcinoma Is Resistant to Anti-Egfr Antibody Cetuximab, but Not Second-Generation EGFR-TKI

English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

English

New Era for Next-Generation Sequencing in Japan

English

Corrigendum to “Analysis of Central Nervous System Efficacy in the J-Alex Study of Alectinib Versus Crizotinib in ALK-positive Non-Small-Cell Lung Cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]

English

A Randomized, Double-Blind, Phase II Study of Ramucirumab Plus Docetaxel vs Placebo Plus Docetaxel in Japanese Patients With Stage IV Non-Small Cell Lung Cancer After Disease Progression on Platinum-Based Therapy

English

Treatment of EGFR Mutation–positive Non–small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report

Oncotarget

Oncology

2018

English

HER2 Genomic Amplification in Circulating Tumor DNA From Patients With Cetuximab-Resistant Colorectal Cancer

Oncotarget

Oncology

2015

English

Three‐year Follow‐up Results From Phase II Studies of Nivolumab in Japanese Patients With Previously Treated Advanced Non‐small Cell Lung Cancer: Pooled Analysis of ONO‐4538‐05 and ONO‐4538‐06 Studies

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kazuhiko Nakagawa

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

NDRG1/Cap43/Drg-1 May Predict Tumor Angiogenesis and Poor Outcome in Patients With Lung Cancer

Aberrant HER3 Ligand Heregulin-Expressing Head and Neck Squamous Cell Carcinoma Is Resistant to Anti-Egfr Antibody Cetuximab, but Not Second-Generation EGFR-TKI

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

New Era for Next-Generation Sequencing in Japan

Corrigendum to “Analysis of Central Nervous System Efficacy in the J-Alex Study of Alectinib Versus Crizotinib in ALK-positive Non-Small-Cell Lung Cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]

A Randomized, Double-Blind, Phase II Study of Ramucirumab Plus Docetaxel vs Placebo Plus Docetaxel in Japanese Patients With Stage IV Non-Small Cell Lung Cancer After Disease Progression on Platinum-Based Therapy

Treatment of EGFR Mutation&#x2013;positive Non&#x2013;small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report

HER2 Genomic Amplification in Circulating Tumor DNA From Patients With Cetuximab-Resistant Colorectal Cancer

Three‐year Follow‐up Results From Phase II Studies of Nivolumab in Japanese Patients With Previously Treated Advanced Non‐small Cell Lung Cancer: Pooled Analysis of ONO‐4538‐05 and ONO‐4538‐06 Studies

Treatment of EGFR Mutation–positive Non–small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report